Headlines about AxoGen (NASDAQ:AXGN) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AxoGen earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 45.383916965603 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s scoring:
Several analysts have recently issued reports on the stock. Leerink Swann reiterated an “outperform” rating and issued a $23.00 target price (up previously from $22.00) on shares of AxoGen in a research report on Saturday, September 30th. Roth Capital restated a “buy” rating and set a $21.00 price target (up from $18.00) on shares of AxoGen in a research report on Tuesday, September 12th. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $18.00 target price on shares of AxoGen in a report on Monday, August 21st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. AxoGen has a consensus rating of “Buy” and an average target price of $17.40.
Shares of AxoGen (AXGN) traded up 0.25% during midday trading on Friday, hitting $20.15. 167,607 shares of the company’s stock were exchanged. The stock’s market cap is $669.79 million. AxoGen has a 1-year low of $7.65 and a 1-year high of $20.40. The stock’s 50 day moving average is $18.92 and its 200-day moving average is $15.84.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $14.40 million. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business’s revenue for the quarter was up 46.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) earnings per share. Analysts predict that AxoGen will post ($0.31) earnings per share for the current fiscal year.
In related news, Director Robert James Rudelius sold 16,143 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $18.00, for a total value of $290,574.00. Following the transaction, the director now owns 43,273 shares in the company, valued at $778,914. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.33% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/axogen-axgn-earns-media-sentiment-rating-of-0-19.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.